Indian Journal of Rheumatology

REVIEW ARTICLE
Year
: 2019  |  Volume : 14  |  Issue : 5  |  Page : 10--18

Drug-induced lupus


Kavadichanda Chengappa G 
 Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India

Correspondence Address:
Dr. Kavadichanda Chengappa G
Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry - 605 006
India

Drug-induced lupus erythematosus (DILE) is an important differential to consider in a clinical setting of mild lupus. Numerous drugs ranging from the classically described procainamide and hydralazine to novel biological agents such as anti-tumor necrosis factors and immune checkpoint inhibitors are implicated in causing DILE. Various pathophysiologic mechanisms such as decreased central tolerance, molecular cross-reactivity, and epigenetic modifications of immune cells are known to play a role in the precipitation of drug-induced autoimmunity. Early recognition and prompt withdrawal of the offending agent is often sufficient to treat these autoimmune manifestations. A thorough knowledge of DILE is essential to ensure better patient care and better understand the role of xenobiotics in precipitating autoimmunity.


How to cite this article:
KavadichandaC. Drug-induced lupus.Indian J Rheumatol 2019;14:10-18


How to cite this URL:
KavadichandaC. Drug-induced lupus. Indian J Rheumatol [serial online] 2019 [cited 2020 Aug 8 ];14:10-18
Available from: http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2019;volume=14;issue=5;spage=10;epage=18;aulast=G;type=0